Harmony Biosciences Holdings, Inc. [Rocket]

Overview

Harmony Biosciences Holdings, Inc.

Add to portfolio

Recent News + Filings (All items)

Date Filed	Type	Description
10/13/2023	8-K	Quarterly results
10/11/2023	SC TO-T/A	Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
10/11/2023	8-K	Quarterly results
10/06/2023	SC 13G/A	BlackRock Inc. reports a 10.2% stake in Harmony Biosciences Holdings, Inc.
10/05/2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/04/2023	8-K	Other Events, Financial Statements and Exhibits  Interactive Data
09/27/2023	SC TO-T/A	Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
Revenues	305.4	159.7	6.0	0.0
Revenue growth	91.2%	2564.6%
Cost of goods sold	55.5	27.7	1.6	0.0
Gross profit	249.9	132.0	4.4	0.0
Gross margin	81.8%	82.6%	73.7%
Sales and marketing	68.1	55.8	44.3	16.9
Research and development	30.4	19.4	69.6	12.4
General and administrative	63.9	39.7	36.4	12.2
EBITA	106.0	26.8	-143.1	-41.4
EBITA margin	34.7%	16.8%	-2386.8%
Amortization of intangibles	18.4	9.8	2.8
EBIT	87.5	17.0	-145.9	-41.4
EBIT margin	28.7%	10.6%	-2433.8%
Pre-tax income	37.4	-36.9	-152.0	-39.9
Income taxes	2.8	0.0	0.0	0.0
Tax rate	7.6%	0.0%	0.0%	0.0%
Net income	34.6	-63.8	-187.2	-70.1
Net margin	11.3%	-40.0%	-3122.7%

Diluted EPS	$0.58	($2.48)	($24.07)	($7.91)
Shares outstanding (diluted)	59.2	25.8	7.8	8.9

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.